[{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"fdd64cda-9a21-415b-a112-87e898241472","acronym":"BGB-3245-AU-001","url":"https://clinicaltrials.gov/study/NCT04249843","created_at":"2021-01-18T20:39:09.280Z","updated_at":"2025-02-25T16:32:04.976Z","phase":"Phase 1","brief_title":"Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors","source_id_and_acronym":"NCT04249843 - BGB-3245-AU-001","lead_sponsor":"MapKure, LLC","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brimarefenib (BGB-3245)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/17/2020","start_date":" 02/17/2020","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"d0abf381-bbfa-4b21-bbe7-740e5caad62b","acronym":"BEAVER","url":"https://clinicaltrials.gov/study/NCT03839342","created_at":"2021-01-18T18:57:15.711Z","updated_at":"2025-02-25T16:59:56.947Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","source_id_and_acronym":"NCT03839342 - BEAVER","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF mutation • BRAF V600K • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600K • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"bc138b32-b1a5-4fc9-8fd6-616343a12a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439279","created_at":"2021-01-18T21:22:11.456Z","updated_at":"2024-07-02T16:35:04.931Z","phase":"Phase 2","brief_title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)","source_id_and_acronym":"NCT04439279","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 03/18/2019","primary_completion_date":" 03/18/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-08"},{"id":"9e89006d-b52b-45d1-b2b6-670282331015","acronym":"","url":"https://clinicaltrials.gov/study/NCT01089101","created_at":"2021-01-17T17:15:45.070Z","updated_at":"2024-07-02T16:35:07.463Z","phase":"Phase 1/2","brief_title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","source_id_and_acronym":"NCT01089101","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 04/19/2010","start_date":" 04/19/2010","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"652c5256-d9cf-4341-a41c-dd696f4d2fa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024929","created_at":"2021-08-27T12:53:01.955Z","updated_at":"2024-07-02T16:35:23.047Z","phase":"","brief_title":"Targeted Therapy to Increase RAI Uptake in Metastatic DTC","source_id_and_acronym":"NCT05024929","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion","tags":["BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/16/2021","start_date":" 07/16/2021","primary_txt":" Primary completion: 02/01/2031","primary_completion_date":" 02/01/2031","study_txt":" Completion: 02/01/2033","study_completion_date":" 02/01/2033","last_update_posted":"2024-01-18"},{"id":"3d9a5b08-ffd8-40b1-8c6f-4f95a249b8b2","acronym":"TRAM-01","url":"https://clinicaltrials.gov/study/NCT03363217","created_at":"2021-01-18T16:35:58.992Z","updated_at":"2024-07-02T16:35:28.095Z","phase":"Phase 2","brief_title":"Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.","source_id_and_acronym":"NCT03363217 - TRAM-01","lead_sponsor":"St. Justine's Hospital","biomarkers":" BRAF • NF1 • KIAA1549","pipe":" | ","alterations":" KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF • NF1 • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-11-27"},{"id":"6121d3c3-a5a8-45ae-b60f-1266584965a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02285439","created_at":"2021-01-18T10:46:08.443Z","updated_at":"2024-07-02T16:35:34.934Z","phase":"Phase 1/2","brief_title":"Study of MEK162 for Children With Low-Grade Gliomas","source_id_and_acronym":"NCT02285439","lead_sponsor":"Children's Hospital Los Angeles","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • BRAF fusion","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 05/04/2016","start_date":" 05/04/2016","primary_txt":" Primary completion: 11/02/2022","primary_completion_date":" 11/02/2022","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-10-03"},{"id":"87c14e4e-dad4-4085-ba55-6c5babc89000","acronym":"","url":"https://clinicaltrials.gov/study/NCT03843775","created_at":"2021-01-18T18:58:38.993Z","updated_at":"2024-07-02T16:35:38.031Z","phase":"Phase 1/2","brief_title":"A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers","source_id_and_acronym":"NCT03843775","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 09/02/2023","primary_completion_date":" 09/02/2023","study_txt":" Completion: 09/02/2023","study_completion_date":" 09/02/2023","last_update_posted":"2023-09-06"},{"id":"6eb97f2c-ec9d-435c-8cbb-be3b4fce8c70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284502","created_at":"2021-01-18T16:13:34.748Z","updated_at":"2024-07-02T16:35:41.554Z","phase":"Phase 1","brief_title":"HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03284502","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" KRAS • BRAF • NRAS • PI3K","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13","tags":["KRAS • BRAF • NRAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-01"},{"id":"77aef55d-2c7b-44a9-bc7d-2c0422f68aad","acronym":"","url":"https://clinicaltrials.gov/study/NCT02296112","created_at":"2021-01-18T10:49:30.368Z","updated_at":"2024-07-02T16:36:29.714Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations","source_id_and_acronym":"NCT02296112","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 04/16/2021","study_completion_date":" 04/16/2021","last_update_posted":"2021-05-28"},{"id":"909396a0-980d-4b31-bbf9-a9299740d296","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386450","created_at":"2021-01-18T05:41:18.193Z","updated_at":"2024-07-02T16:37:15.606Z","phase":"Phase 2","brief_title":"AZD6244 in Children With Low-Grade Gliomas","source_id_and_acronym":"NCT01386450","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-12-12"}]